Trevena, Inc. (TRVN)
- Previous Close
0.3520 - Open
0.3532 - Bid 0.3000 x 100
- Ask 0.4201 x 200
- Day's Range
0.3232 - 0.3895 - 52 Week Range
0.3000 - 3.2800 - Volume
423,648 - Avg. Volume
208,579 - Market Cap (intraday)
6.782M - Beta (5Y Monthly) 1.10
- PE Ratio (TTM)
-- - EPS (TTM)
-3.1600 - Earnings Date May 13, 2024 - May 17, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.00
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.
www.trevena.comRecent News: TRVN
Performance Overview: TRVN
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TRVN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TRVN
Valuation Measures
Market Cap
6.87M
Enterprise Value
10.14M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.53
Price/Book (mrq)
--
Enterprise Value/Revenue
3.24
Enterprise Value/EBITDA
-0.28
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-49.40%
Return on Equity (ttm)
-1,014.58%
Revenue (ttm)
3.12M
Net Income Avi to Common (ttm)
-40.29M
Diluted EPS (ttm)
-3.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
32.98M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-21.94M